Multiple Sclerosis - From Who Gets It to How Much Does it Cost to Treat
Program Description / Statement of Need:
Multiple sclerosis (MS) is an acquired, inflammatory and immune mediated disorder of the central nervous system that affects 350,000-450,000 persons in the U.S. Disease Modifying Treatments (DMTs) for MS aim to reduce the frequency and severity of relapses, delay disability, and postpone the onset of the progressive phase of MS. Most agents are parenteral and self-administered. Recently, a physician-infused DMT and oral agents are entering the market.
The management of biologics, parenteral products, increased utilization of specialty pharmacy have all been listed as major health care challenges. Given the potential evolution of MS treatment landscape into orals; and the likelihood of a crowded MS marketplace, the value proposition of these options are likely to be evaluated and scrutinized more carefully by decision-makers. Healthcare providers need to become aware of new and developing treatments.
Target Audience:
This activity has been designed to meet the educational needs of Physicians, Nurses, Physician Assistants, Nurse Practitioners, and other health care professionals who are interested in identifying patients with MS as well as disease management programs for MS patients.
Program Objectives:
The learning objectives for this program are to enable participants, at the conclusion of the program, to able to:
- Understand MS symptoms, epidemiology, comorbidities, and costs
- Discuss treatment goals, existing and developmental parenteral and oral medications to treat MS, place of products in therapy as it relates to their value proposition based on Benefit/Risk as it relates to their efficacy, safety, tolerability and value profile
- Become familiar with adherence to therapies, and likelihood of therapy to achieve treatment goals
- Understand costs, reimbursement and the managed care budget impact of MS agents
- Read the learning objectives and faculty disclosures above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
- View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Take the post-test
- Complete the program evaluation and CME registration. A CE certificate will be emailed to you within 30 days.
Accreditation:
Physicians:This program has been reviewed and is acceptable for up to 1 Prescribed credit hours by The American Academy of Family Physicians. AAFP Prescribed credit is accepted by The AMA as equivalent to AMA PRA Category I for AMA The Physicians' Recognition Award. When applying for the AMA PRA, Prescribed hours earned must be reported as Prescribed hours, not as Category I. (This statement applies to all Physicians, not just Family Physicians). Educational Review Systems is also approved for physician continuing education by the state of Florida.
Pharmacists: Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1 hour (0.1CEUs). ACPE # 0761-9999-10-116-H01-P; 0761-9999-10-116-H01-T Educational Review Systems is also approved for pharmacy continuing education by the state of Florida.
Release Date: August 25, 2010
Expiration Date: August 24, 2011
Faculty:Randall T. Schapiro, M.D.
Faculty Disclosures
Viewing Requirements:
Internet Explorer 5.5
*Adobe Acrobat Reader
*Required to view Printable PDF Version
Mac OS 10.2.8
Safari
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
On-line symposium:
-
Instructions:
Download the Presentation (optional)
Complete the Symposium Evaluation and Request CE Certificate
Supported through an educational grant from:
| Bayer Healthcare |  |
Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.